U.S., Nov. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07935317) titled 'A Study of Tersolisib (LY4064809) and Abemaciclib With Hormone Therapies in Participants With PIK3CA-Mutated Early Breast Cancer' on Nov. 09.
Brief Summary: The main purpose of this study is to compare two ways of giving the anti-cancer medicines abemaciclib and hormone therapy with tersolisib in participants with early breast cancer that has a genetic mutation (PIK3CA mutation).
For each participant, the study will last up to 56 weeks and include 12 visits.
Study Start Date: Dec., 2026
Study Type: INTERVENTIONAL
Condition:
Breast Neoplasms
Intervention:
DRUG: Abemaciclib
Administered orally
DRUG: Tersolisib
Administered o...